Autres langues Lyra Therapeutics, Inc.

Actions

LYRA

US55234L1052

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 02/05/2024			Varia. 5j.	Varia. 1 janv.
4,63 ^USD	-11,81%		-11,47%	-11,64%

30/04	Lyra Therapeutics, Inc. annonce ses résultats pour le premier trimestre clos le 31 mars 2024	CI
19/04	Lyra Therapeutics, Inc. annonce des changements au sein de son conseil d'administration	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Lyra Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	30/04
Lyra Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update	30/04
Lyra Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	26/04
Lyra Therapeutics, Inc. Announces Board Changes	19/04
Lyra Therapeutics Files $300 Million Mixed Shelf Offering	22/03
Lyra Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	21/03
Lyra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update	21/03
Lyra Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	01/03
Lyra Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	07/11
Lyra Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update	07/11
Lyra Therapeutics to Participate in Upcoming Investor Conferences	07/11
Lyra Therapeutics Announces Appointment of Ronan O’Brien as Chief Legal Officer	16/10/23
Lyra Therapeutics, Inc Announces Appointment of Ronan O?Brien as Chief Legal Officer	16/10/23
Lyra Therapeutics Says Phase 2 Trial for Chronic Rhinosinusitis Treatment Meets Primary Endpoint	12/09/23
Lyra Therapeutics Announces Positive Topline Results from BEACON Phase 2 Study of LYR-220 for the Treatment of Chronic Rhinosinusitis (CRS) in Patients with Prior Ethmoid Sinus Surgery	12/09/23
Lyra Therapeutics Announces Positive Topline Results from Beacon Phase 2 Study of LYR-220 for the Treatment of Chronic Rhinosinusitis in Patients with Prior Ethmoid Sinus Surgery	12/09/23
Lyra Therapeutics to Participate in Upcoming Investor Conferences	06/09/23
Lyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN I Trial of LYR-210 for the Treatment of Chronic Rhinosinusitis	29/08/23
North American Morning Briefing : China Angst -2-	15/08/23
Lyra Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	08/08/23

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Lyra Therapeutics, Inc.

Actions

LYRA

US55234L1052

Autres langues

Filtres